tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Alector sees FY25 revenue view $13M-$18M, consensus $12.56M
PremiumThe FlyAlector sees FY25 revenue view $13M-$18M, consensus $12.56M
12d ago
Alector reports Q2 EPS (30c), consensus (47c)
Premium
The Fly
Alector reports Q2 EPS (30c), consensus (47c)
12d ago
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment
Premium
Company Announcements
Alector’s Latozinemab Study: A Promising Step in Neurodegenerative Disease Treatment
19d ago
Alector price target raised to $10 from $7 at H.C. Wainwright
PremiumThe FlyAlector price target raised to $10 from $7 at H.C. Wainwright
3M ago
Alector’s Growth Potential Highlighted by Strong Financials and Promising Trial Developments
Premium
Ratings
Alector’s Growth Potential Highlighted by Strong Financials and Promising Trial Developments
3M ago
Alector’s Clinical Progress and Financial Stability Drive Buy Rating
Premium
Ratings
Alector’s Clinical Progress and Financial Stability Drive Buy Rating
3M ago
Cautious Outlook on Alector: Limited Prospects for Latozinemab and Financial Uncertainty Drive Sell Rating
PremiumRatingsCautious Outlook on Alector: Limited Prospects for Latozinemab and Financial Uncertainty Drive Sell Rating
6M ago
Alector’s Earnings Call: Progress Amid Challenges
Premium
Company Announcements
Alector’s Earnings Call: Progress Amid Challenges
6M ago
Promising Clinical Data and Scientific Rationale Support Alector’s Therapeutic Approach in Neurodegenerative Diseases
Premium
Ratings
Promising Clinical Data and Scientific Rationale Support Alector’s Therapeutic Approach in Neurodegenerative Diseases
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100